PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17357832-0 2007 Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells. Gabexate 37-54 tumor necrosis factor Homo sapiens 112-121 17357832-6 2007 The NF-kappaB activity of both cell lines was increased by the addition of TNF-alpha, while TNF-alpha-induced NF-kappaB activity was suppressed by prestimulation with GM in a dose-dependent manner. Gabexate 167-169 tumor necrosis factor Homo sapiens 92-101 17357832-7 2007 Caspase 3 and 7 activity was significantly increased by TNF-alpha with GM stimulation. Gabexate 71-73 tumor necrosis factor Homo sapiens 56-65 17357832-9 2007 These results indicate that GM inhibits TNF-alpha-induced NF-kappaB activation and enhances apoptosis in human pancreatic cancer cell lines. Gabexate 28-30 tumor necrosis factor Homo sapiens 40-49 12682486-2 2003 We examined whether gabexate mesilate inhibits tumor necrosis factor-alpha-induced expression of leukocyte adhesion molecules in cultured endothelial cells. Gabexate 20-37 tumor necrosis factor Homo sapiens 47-74 12682486-12 2003 MEASUREMENTS AND MAIN RESULTS: Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced increases in the endothelial expression of E-selectin and intercellular adhesion molecule-1 by inhibiting the transcription. Gabexate 31-48 tumor necrosis factor Homo sapiens 63-90 12682486-13 2003 Tumor necrosis factor-alpha-induced increase in DNA binding of p65 was inhibited by gabexate mesilate through inhibition of the nuclear translocation of p65. Gabexate 84-101 tumor necrosis factor Homo sapiens 0-27 12682486-14 2003 Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs. Gabexate 0-17 tumor necrosis factor Homo sapiens 32-59 12682486-17 2003 Gabexate mesilate might reduce lipopolysaccharide-induced pulmonary vascular injury not only by inhibiting monocytic tumor necrosis factor-alpha production but by inhibiting the expression of endothelial leukocyte adhesion molecules. Gabexate 0-17 tumor necrosis factor Homo sapiens 117-144 12649382-0 2003 Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. Gabexate 0-17 tumor necrosis factor Homo sapiens 87-114 12649382-1 2003 Gabexate mesilate, a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate 0-17 tumor necrosis factor Homo sapiens 169-196 12649382-1 2003 Gabexate mesilate, a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate 0-17 tumor necrosis factor Homo sapiens 198-207 12649382-3 2003 In the present study, we analyzed the mechanism(s) by which gabexate mesilate inhibits LPS-induced TNF-alpha production in human monocytes in vitro. Gabexate 60-77 tumor necrosis factor Homo sapiens 99-108 12649382-4 2003 Gabexate mesilate inhibited the production of TNF-alpha in monocytes stimulated with LPS. Gabexate 0-17 tumor necrosis factor Homo sapiens 46-55 12649382-7 2003 These observations strongly suggest that gabexate mesilate inhibited LPS-induced TNF-alpha production in human monocytes by inhibiting activation of both NF-kappaB and AP-1. Gabexate 41-58 tumor necrosis factor Homo sapiens 81-90 12649382-8 2003 Inhibition of TNF-alpha production by gabexate mesilate might explain at least partly its therapeutic effects in animals given LPS and those in patients with sepsis. Gabexate 38-55 tumor necrosis factor Homo sapiens 14-23 11220636-11 2001 The present study shows that the inhibitory effect of GM on the TNFalpha production of activated human monocytes is mediated by the suppression of NFkappaB activation, while the mechanism of UTI inhibiting TNFalpha production of human monocytes may be due to the inhibition of either the translation or secretion of TNFalpha. Gabexate 54-56 tumor necrosis factor Homo sapiens 64-72 11220636-8 2001 GM decreased the TNFalpha production of LPS-stimulated monocytes as shown by the inhibition of mRNA expression and increased the IL-10 production of LPS-stimulated monocytes. Gabexate 0-2 tumor necrosis factor Homo sapiens 17-25 12025532-6 2002 The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4. Gabexate 25-42 tumor necrosis factor Homo sapiens 95-104 12025532-6 2002 The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4. Gabexate 25-42 tumor necrosis factor Homo sapiens 293-302 10037314-8 1999 Gabexate mesilate showed a little inhibition of TNF-alpha production by monocyte without LPS stimulation. Gabexate 0-17 tumor necrosis factor Homo sapiens 48-57 10037314-9 1999 On the other hand, gabexate mesilate significantly inhibited TNF-alpha production by LPS stimulated monocyte. Gabexate 19-36 tumor necrosis factor Homo sapiens 61-70 10037314-12 1999 CONCLUSIONS: Reduction of systemic inflammatory response syndrome duration after esophagectomy by the continuous administration of gabexate mesilate started before operation may be through the suppression of TNF-alpha production capacity and Mac-1 expression on monocytes immediately after operation, and to suppression of increase in serum IL-6 level. Gabexate 131-148 tumor necrosis factor Homo sapiens 208-217 9878311-10 1998 RESULTS: GM inhibited the PAI-1 synthesis of HUVECs stimulated with TNFalpha in a dose-dependent manner as shown by the mRNA expression. Gabexate 9-11 tumor necrosis factor Homo sapiens 68-76 9878311-12 1998 In contrast, both GM and UTI significantly inhibited the ICAM-1 expression on HUVECs stimulated with TNFalpha. Gabexate 18-20 tumor necrosis factor Homo sapiens 101-109 27140710-6 2016 Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup. Gabexate 166-174 tumor necrosis factor Homo sapiens 0-27 27140710-6 2016 Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup. Gabexate 212-220 tumor necrosis factor Homo sapiens 0-27